This Article Full Text Full Text (PDF) All Versions of this Article: 93/8/2948    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Visekruna, M. Articles by McKiernan, F. E. PubMed PubMed Citation Articles by Visekruna, M. Articles by McKiernan, F. E. Related Collections Calcium and Bone Metabolism Female Endocrinology

Severely Suppressed Bone Turnover and Atypical Skeletal Fragility

Center for Bone Disease, Marshfield Clinic, Marshfield, Wisconsin 54449

Address all correspondence and requests for reprints to: Maja Visekruna, M.D., Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin 54449. E-mail: visekruna.maja{at}marshfieldclinic.org.

Context: Since their introduction into clinical medicine, bisphosphonates have revolutionized clinical osteoporosis care. Ironically, in rare circumstances, long-term, combined anti-remodeling therapy may be associated with skeletal harm.

Evidence Acquisition: We report atypical skeletal fragility in three subjects after long-term, combined anti-remodeling therapy.

Evidence Synthesis: Three subjects experienced spontaneous or minimal-trauma chalk-stick type metadiaphyseal femoral fractures while on long-term bisphosphonate therapy. The fracture location, type, bilaterality, prodromal pain, and delayed healing were atypical for uncomplicated postmenopausal osteoporosis. All three subjects had concomitant circumstances (endogenous estrogen) or medications (glucocorticoids, hormone replacement therapy, and raloxifene) that likely suppressed bone remodeling beyond the effect of the bisphosphonate alone. Biochemical markers of bone turnover were very low or in the low premenopausal range. Double tetracycline-labeled bone biopsy showed very low activation frequency in one subject and limited single tetracycline label in a second consistent with severely suppressed bone turnover (SSBT). These three cases resemble previous descriptions of SSBT.

Conclusion: Atypical skeletal fragility may signify SSBT in the setting of long-term, combined anti-remodeling therapy. We speculate that osteoclast tolerance for pharmacological suppression may vary among individual patients and that in some cases combined anti-remodeling therapy may result in skeletal harm.